Mary Katherine Cella Shultz

Such an exciting publication! Initiate SGLT2is EARLY! Congratulations @Zac0x !

Great time at @ACCinTouch #ACC.23 in Nola! @accpcardprn #ACCCVT @MidAmericaHeart

Please join PGY2 @MKShultz_PharmD as she EXPLORE(R)s the "Hype for Hypertrophy: Updates in Hypertrophic Cardiomyopathy." She gives us updates on Mavacamten and beyond for contemporary management of HCM!

Nurses often say they have a gut feeling “the patient is going to crash” THIS is why you should listen ncbi.nlm.nih.gov/pmc/articles/P…

EMPULSE Trial Publication: Empa in patients hospitalized for acute HF | ⁦@NatureMedicine⁩ ⁦@AdriaanVoors⁩ ⁦@ShelleyZieroth⁩ ⁦@mpsotka⁩ ⁦@MichaelNassifMD⁩ ⁦@jteerlinkmd⁩ nature.com/articles/s4159…

Top 5 strategies to ⬇️ ☠️ and re-🏨 in HFrEF 1. In-🏨 ARNI+BB+MRA+SGLT2i 2. In-🏨 ARNI+BB+MRA+SGLT2i 3. In-🏨 ARNI+BB+MRA+SGLT2i 4. In-🏨 ARNI+BB+MRA+SGLT2i 5. In-🏨 ARNI+BB+MRA+SGLT2i

"Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance" @JCardFail 💠4-drug diuretic regimen in this study = fascinating; So much practice variation around world 💠Acetazolamide 250 q8, lasix 200 q6, metolazone 10 q12, spiro 100 BID! onlinejcf.com/article/S1071-…

#EMPEROR-Preserved trial: empagliflozin reduces the risk of a composite of #cardiovascular death or hospitalisation for #heartfailure in patients with #HFpEF with or without #diabetes #ESCCongress

We know these people 😊

Our #COVID19 statement on today's status is below. #GetVaccinated

Hot 🔥new paper alert!🚨Milrinone and dobut finally step into the squared circle 🤼‍♂️ #TwitteRx @accpcardprn @accpcritprn nejm.org/doi/full/10.10…

ACLS Training ✅✅✅ These PGY1s coming to a code near you! @VUMCRxResidency @TJWertRx @JackPluenneke @MKShultz_PharmD